KMT2A and acute myeloid leukemia: Notably, preclinical data suggest an effective role of these agents in specific subtypes of AML (KMT2A fusions, NPM1 or chromatin/spliceosome genes mutations), while others, such as TP53 AMLs, seem to be resistant [184].